Peritoneovenous shunting for nongynecologic malignant ascites

Cancer

Volumn 91, Issue 7, 2001, Pages 1247-1255

  Bieligk, Samuel C ^a,c   Calvo, Benjamin F ^b   Coit, Daniel G ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Diuresis; Malignant ascites; Paracentesis; Peritoneal cytology; Peritoneovenous shunt

Indexed keywords

ADULT; AGED; ARTICLE; ASCITES; BREAST CANCER; CANCER SURVIVAL; FEMALE; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; PRIORITY JOURNAL; SHUNTING; TREATMENT INDICATION; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; UROGENITAL TRACT TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; BLOOD UREA NITROGEN; CREATININE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PALLIATIVE CARE; PERITONEOVENOUS SHUNT; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0035312427     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010401)91:7<1247::AID-CNCR1125>3.0.CO;2-W     Document Type: Article

References (31)

1. On the treatment and prognosis of malignant ascites: Is the survival time determined when the abdominal paracentesis is needed?
2. Gastrointestinal malignancy: Rational for adjuvant therapy using early postoperative intraperitoneal chemotherapy
3. Malignant ascites
4. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer
5. Peritoneohyphen;venous shunting for ascites
6. Peritoneo-venous shunting system for surgical management of ascites
7. The treatment of resistant malignant ascites by insertion of a peritoneo-atrial Holter valve
8. Selection of patients with malignant ascites for a peritoneovenous shunt
9. Peritoneovenous shunts palliate malignant ascites
10. Malignant ascites: A comparison of peritoneovenous shunting and nonoperative management
11. Peritoneovenous shunts for palliation of the patient with malignant ascites
12. Palliation of malignant ascites by the LeVeen peritoneo-venous shunt
13. Care of patients with ascites
14. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma
15. Peritoneovenous shunting for malignant ascites
16. Malignant ascites: Clinical and experimental observations
17. A critical evaluation of 3000 cytologic analyses of pleural fluid, ascitic fluid, and pericardial fluid
18. Peritoneovenous shunts in malignant ascites
19. LeVeen shunts in patients with intractable malignant ascites
20. Peritoneovenous shunt for intractable ascites of hepatic, nephrogenic, and malignant causes
21. Peritoneovenous shunts for malignant ascites
22. Peritoneovenous shunting in the management of malignant ascites
23. Peritoneovenous shunting for cirrhotic versus malignant ascites
24. Peritoneovenous shunt for palliation of malignant ascites
25. Management of malignant ascites
26. Disseminated intravascular coagulation with the peritoneovenous shunt
27. Peritoneovenous shunt for palliation of gynecologic malignant ascites
28. Coagulopathy following peritoneovenous shunting
29. Management of malignant ascites with peritoneovenous shunting
30. Peritoneovenous shunts in the management of malignant ascites
31. Diuretics in malignant effusions and edemas of generalized cancer